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Abstract 
Asymmetric telechelic α-hydroxyl-ω-(carboxylic acid)-poly(ε-caprolactone) (HA-PCL), 
α-hydroxyl-ω-(benzylic ester)-poly(ε-caprolactone) (HBz-PCL) and an asymmetric 
telechelic copolymer α-hydroxyl-ω-(carboxylic acid)-poly(ε-caprolactone-co-γ-
butyrolactone) (HA-PCB) were synthesized by ring-opening polymerization of  ε-
caprolactone (CL). CL and CL/γ-butyrolactone mixture were used to obtain  
homopolymers and copolymer respectively at 150°C and 2 h using ammonium 
decamolybdate (NH4) [Mo10O34] (Dec) as catalyst. Water (HA-PCL and HA-PCB) or 
benzyl alcohol (HBz-PCL) were used as initiators. The three polylactones reached 
initial molecular weights between 2000-3000 Da measured by proton nuclear magnetic 
resonance (1H-NMR). Compression-molded polylactone caplets were allowed to 
degrade in 0.5 M aqueous p-toluenesulfonic acid at 37°C and monitored up to 60 days 
for weight loss behavior. Data showed that the copolymer degraded faster than the PCL 
homopolymers, and that there was not difference in the weight loss behavior between 
HA-PCL and HBz-PCL. Caplets of the three polylactones containing 1% (w/w) 
hydrocortisone were placed in two different buffer systems, pH 5.0 with citrate buffer 
and pH 7.4 with phosphate buffer at 37°C, and monitored up to 50 days for their release 
behavior. The release profiles of hydrocortisone presented two stages. The introduction 
of a second monomer in the polymer chain significantly increased the release rate, being 
the degradation rate for HA-PCB faster than those for HBz-PCL and HA-PCL. At the 
pH studied, only slight differences on the liberation profiles were observed. SEM 
micrographs indicate that hydrolytic degradation occurred mainly by a surface erosion 
mechanism.  
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 1. Introduction 
Biodegradable polyesters and co-polyesters have been the focus of extensive research 
for several decades, as a result of their ease of manufacturing and desirable 
characteristics. Their ranges of physical properties and hydrolytic degradation profiles 
have made them attractive candidates for use in a variety of biomedical products such as 
degradable sutures, temporary orthopedic fixtures and controlled pharmaceutical 
delivery matrices. Biodegradable materials degrade in vivo under a controlled manner, 
yielding nontoxic small molecules that can be excreted from the body [1].  
Poly (ε-caprolactone) (PCL) is a hydrophobic and biodegradable polymer that has found 
widespread uses in biomedical applications [2]. PCL is a synthetic polymer used for 
fibrous meshes and porous scaffolds in the field of tissue engineering. [3] However, the 
high degree of crystallinity decreases its biocompatibility with soft tissues and lowers 
its rate of biodegradability. PCL shows a high degree of permeability toward low 
molecular weight drugs (<400 Da), and this property made it attractive for the 
manufacture of long-term and diffusion-controlled delivery drug delivery systems. In 
the scope of the local drug delivery applications, PCL has been successfully tested as a 
vehicle for slow release of drugs at tumor reactions sites [4, 5].  
Ring opening polymerization of lactones provides a convenient route to obtain 
biodegradable aliphatic polyesters, being PCL the most important member of this 
family. Different catalysts have been used to catalyze the polymerization and low-
molecular weight alcohols can be used as initiators and to control the final polymer 
molecular weight. We have reported the use of ammonium decamolybdate 
((NH4)8[Mo10O34] as an efficient catalyst to obtain aliphatic polyesters and their 
copolymers with different architectures [5, 6]. In this work, we have used this catalyst to 
obtain the polymers tested for degradation and as drug delivery carriers. 
The rate of PCL hydrolysis can be accelerated by copolymerization with other lactones. 
In that regard, copolymers of CL with δ-valerolactone and DL-lactide (e.g. a 
commercial suture MONOCRYL, Ethicon) show higher degradation rates [7]. In the case 
of poly (ε-caprolactone-co-γ-butyrolactone) (PCB), the appearance of new physical 
properties and the observance of higher rate of degradation make them amenable for 
tailored applications as biodegradable materials [6, 8]. Therefore biodegradable polymer 
with desired degradation rates should be synthesized and the degradation rate should be 
determined by an effective method. Generally, in vitro degradation of biodegradable 
polymer is studied in buffer solutions. However, the degradation rates of some polymers 
are very slow, and for PCL, it will take more than 1 year to get a complete degradation 
of the polymeric matrices [9].  
Hydrocortisone ((11β) 11,17,21-trihydroxy-(11beta)-pregn-4-ene-3,20-dione) is a 
hydrophobic corticosteroid drug used in the treatments of allergies and inflammations. 
It relieves symptoms related to certain hormone shortage and has an 
immunosuppressive action. Hydrocortisone is applied as topical and oral administration 
or intravenous injection. It can also be combined with antibiotics and antifungal agents 
to treat infections. Hydrocortisone has been used to treat certain types of cancer such as 
leukemia, lymphoma and multiple myeloma [10]. In this study, hydrocortisone was used 
as a drug model.  
A common procedure to test different systems for controlled release applications is the 
incorporation of the active agent into a biodegradable polymer matrix, followed by the 
study of its degradation behavior under hydrolytic conditions. Degradation rates for 
polymers mainly reside on polymer characteristics, such as chemical structure, water 
permeability (hydrophilicity/hydrophobicity), morphology and molecular weight.  It is 
known that aliphatic polyesters provide a good permeable system for steroid release. 
However, degradation times observed for these polymers are relatively long [11,12]. For 
poly(ε-caprolactone), degradation can be accelerated by using (a) low-molecular weight 
samples and (b) by copolymerization with other monomers such as γ-butyrolactone, BL.  
In this article, degradation and hydrocortisone release behavior from caplets made from 
(a) poly(ε-caprolactone) with different end groups, and (b) (ε-caprolactone-co-γ-
butyrolactone) (HA-PCB) were studied. Effects of end-groups and copolymerization 
(by insertion of butyrolactone onto the polymeric chains) on degradation and of drug 
release from these polymers were evaluated. Results show that significant higher rates 
of degradation and hydrocortisone release are obtained for the copolymer system.  
2. Experimental 
2.1 Materials 
CL (Aldrich Chemicals Co.), BL (Aldrich) were dried over calcium hydride and 
destilled under reduced pressure before used. Distilled water was purchased from Baker. 
Benzyl alcohol (BzOH),  p- toluenesulfonic acid and hydrocortisone were purchased 
from Aldrich and used without further purification. Ammonium heptamolybdate 
tetrahydrate (NH4)6 [Mo7O24] (Hep)(Fluka) was grounded in a mortar and passed 
through a 100 mesh sieve before used [2, 5]. 
2.2 Synthesis of poly(ε-caprolactone)s and poly(ε-caprolactone-co-γ-butyrolactone) 
α-Hydroxyl-ω-(carboxylic acid)-poly(ε-caprolactone) (HA-PCL),    α-hydroxyl-ω-
(benzyl ester)-poly(ε-caprolactone) (HBz-PCL) and α-hydroxyl-ω-(carboxylic acid)-
poly(ε-caprolactone-co-γ-butyrolactone) (HA-PCB) were synthesized by ring-opening 
polymerization with ammonium decamolybdate (NH4)8[Mo10O34] (Dec) as catalyst, 
using an initial monomer/catalyst ratio of 20,000, as described elsewhere[5, 6]. Water was 
used as initiator for HA-PCL and HA-PCB, and benzyl alcohol for HBz-PCL. A 
monomer/initiator ratio of 20 was used, in order to obtain polymers in the range 
between 2000 and 3000 Da. Polymerizations were carried out in 100 mL vials 
previously dried and purged with dry nitrogen. Vials were stoppered with a rubber 
septum and placed in a thermostated bath at 150°C for 2 h. Final polymers were 
carefully crystallized from chloroform/methanol and dried under vacuum. No monomer 
was detected by 1H-NMR in the final polymer used for the tests. 
NMR data for HA-PCB copolymer: [6]  1H NMR (300 MHz, CDCl3, ppm): δ 
4.12 (t, 2H, [−CH2O−], BL), 4.06 (t, 2H, [−CH2O−], CL), 3.68 (t, 2H, [−CH2OH], BL), 
3.64 (t, 2H, [−CH2OH], CL), 2.39 (t, 2H, [−CH2CO2−], BL), 2.31 (t, 2H, [−CH2CO2−], 
CL), 1.96 (q, 2H, [−CH2−], BL), 1.65 (m, 4H, [−(CH2)2−], CL), 1.38 (q, 2H, [−CH2−], 
CL). 13C NMR (50 MHz, CDCl3, ppm): δ 176.80 [end-group −COOH], 173.60 [ester 
end-group −C=O], 173.41 [ester −C=O], 173.25 and 172.70  [ester −C=O, BL], 64.19 
[−CH2O−, CL], 63.96  [−CH2O−, CL], 63.14  [−CH2O−, BL], 62.29 [−CH2OH, CL] and 
61.68 [−CH2OH, BL], 34.04 [−CH2CO2−, CL], 33.92 [−CH2CO2−, CL], 33.83 and 
33.46 [−CH2CO2−, CL],  32.08 [−CH2CH2OH], 30.58  [−CH2COO−, BL] , 28.14 
[−CH2CH2OCO−, CL], 25.33 [−CH2(CH2)2OCO−, CL], 25.12 [−CH2(CH2)2OCO−, 
CL], 24.50 [−CH2(CH2)2OCO−, CL], 24.38 [−CH2CH2CO2−, CL], 
24.18[−CH2CH2COO−, CL], 23.87 [−CH2(CH2)2OCO−, BL].    
 
2.3 Caplets preparation 
HA-PCL, HBz-PCL homopolymers and HA-PCB copolymer were compression molded 
at 4 tons and room temperature to yield caplets of 7 mm diameter and 1.5 mm thickness. 
Weights were in the range between 45 and 55 mg.  
2.3.1 Preparation of Caplets containing 1% hydrocortisone (w/w) 
HA-PCL, HBz-PCL homopolymers and HA-PCB copolymer were mixed in solution 
(THF as solvent) with 1% (w/w) of hydrocortisone; the solution previously frozen was 
dried at vacuum and room temperature. The powder was compression molded at 4 tons 
and room temperature to yield caplets of 7 mm diameter and 1.5 mm thickness and 
weights in the range between 45 and 55 mg.  
2.4 In vitro hydrocortisone release studies of polylactones caplets  
Hydrocortisone release was evaluated by UV-vis spectroscopy. The polylactones caplets 
(50mg and 7.0 X 1.5 mm) were placed in 15 ml of 0.1M aqueous citrate buffer at pH 
5.0 or 0.1M aqueous phosphate buffer at pH 7.4 (both containing 0.05% w/v sodium 
azide as preserving agent) in a oven incubator at 37°C. The hydrocortisone 
concentration (248 nm) was determined by UV-Vis spectrophotometer 8453 (Agilent 
Germany), taking upper layer aliquot (3.0 ml) for UV-Vis measurement. Samples were 
then returned to the original solution. Three runs were made for each sample tested at 
pH = 5.0. 
2.5 In vitro degradation 
The polylactones caplets previously weighed were placed in 50 mL falcon tubes 
containing 10 mL of 0.5 M aqueous p-toluenesulfonic acid (pH = 0.7) and maintained at 
37°C in an incubator. Samples were removed at select times within 58 days, filtered 
through a 0.45-μm membrane (Gelman Laboratory Nylaflo ®), and washed with 
distilled water. The solid samples were collected and dried in vacuum at room 
temperature over 3 days. The remaining polymer solid was then weighed to determine 
the dry weight. The percentage of the weight remaining was calculated from the ratio of 
the dry weight divided by the initial weight of the polymers. Three runs were made for 
each sample. 
2.6 Analysis and characterization  
Differential scanning calorimetry (DSC) analysis was carried in a Mettler 
Toledo (DSC 822e) calorimeter. Samples weighting 5 to 15 mg, were sealed in 
aluminum pans. Samples were heated at 10 °C min-1 under nitrogen purge from 25 to 
80ºC, then cooled at -90ºC, hold at this temperature for 12 minutes, and reheated at 10 
°C min-1 from -90 to 80ºC. Data were recorded from the first run. 
 Surface morphologies of polymers films were recorded with a scanning electron 
microscope (SEM) LEICA S420σ, after coating samples with gold. 
 Wide-angle X-ray diffraction (WAXD) patterns were obtained by means of a 
Phillips PW 1130 diffractometer (Cu Kα radiation), at a scan rate of 2° min-1 over the 5-
35 2θ. 
 Solution 1H spectra were recorded at room temperature on a Varian Unity Inova 
500 (500 MHz 1H) spectrometer. Chloroform-d (CDCL3) was used as solvent. Spectra 
were referenced to the residual solvent signal at 7.26 ppm. 
GPC-MALLS spectra were determined using a multidetector system: a multi-
angle light scattering (MALS) Dawn EOS photometer, that measures the intensity of the 
scattered light at 16 angular locations ranging from 12.5° to 164.9°; a ViscoStar 
viscometer for measuring the differential pressure in a four-capillary bridge; an 
interferometer refractometer detector (Optilab rEX) as a concentration detector. The 
MALS photometer uses a GaAs laser operating at a nominal wavelength of 690 nm. The 
chromatographic set-up used consists of an Alliance HPLC Waters 2695 Separation 
Module having a vacuum degassing facility online, an autosampler, a quaternary pump, 
a columns thermostat, and a Waters 2414 Differential Refractometer for determining the 
distribution of molecular weight. A bank of four columns with the following 
characteristics was used: HSPgel: HR 1.0, HR 2.5, HR 4.0, and HR MB-M (dimensions 
150 mm x 6.0 mm) with pore sizes of 50 Å, 500Å, 1.0E+4 and a mixed bed pore size 
(100 Å to 1.0E+6 Å) respectively, and particle size 3 and 5 µm. HPLC Tetrahydrofuran 
(THF), previously filtered (in a 0.45 µm pore size filter) and degassed, was used as the 
eluent. Typical conditions were: flow rate of 0.5 ml/min; 100 µL injection volume; 
analysis time per sample 35 min. The temperature of the columns was controlled at 33 
ºC by the thermostat. The relative values of molecular weight distribution were obtained 
by using Alliance Empower software. However, to obtain the absolute values, the 
ASTRA software version 5.3.2.10 (Wyatt Technology Corp., Santa Barbara, CA) was 
used.  
3. Results and discussion 
3.1 Characterization of polymer samples 
 The number-average molecular weights for the three studied polylactones, and 
thermal and degradation properties for their 1% hydrocortisone composites, are 
summarised in Table I. 
Number-average molecular weights (Mn) and copolymer composition were 
calculated by 1H-NMR [5,6]. The number-average molecular weights of the three 
polylactones were in the range of 2000-3000 Da. It was found that a 7% of BL insertion 
was achieved. Mn and Mw values are overestimated by GPC-MALLS, but give an idea 
of the samples polydispersities. 
Because of the importance of the crystallinity on the degradation, we carried out 
a detailed study on the crystallinity of our materials. 
Degree of crystallinity is closely related with the molecular weight Mn, and this 
value increases as the molecular weight decreases. The three precipitated polylactones 
possess high degrees of crystallinity, in the range 78 to 84 (HA-PCL > HA-PCB > HBz-
PCL), due to CL segments crystallization[13, 14]. For our copolymer HA-PCB we did not 
find a significant lowering in CL segments crystallinity found by other authors [8]. It is 
reported that PCL melting points occur in the range of 59-64 °C, and the values of Tm 
depend upon the crystallite size [14]. Observed melting points obtained from the 
endotherm maxima for the polymers studied here are different (see Fig. 1 and Table 1), 
with copolymer HA-PCB showing a significant lower value than those recorded for the 
homopolymers. Both homopolyesters show higher melting points than copolymer, being 
lower that for HBz-PCL (Tm = 60.3 °C). If we relate this value to the size of the PCL 
crystallites, it is obvious that the bulky benzyl end-group interferes the ordering for 
crystallization more than carboxylic acid groups, and that the inclusion of a comonomer 
in the main chain has even a stronger effect. In the second scan, after melting at 
approximately 10ºC lower than in the first scan, the same trend is observed for the 
melting point, indicating again the difference in crystallites sizes, but the amount of 
crystallinity for co-polymer HA-PCB is higher than for homopolymers HA-PCL and 
HBz-PCL (63, 60, 59% respectively). This difference is explained by the faster 
crystallization of the shorter segments of caprolactone in the copolymer.  
The same trends observed for precipitated polylactones are found for caplets 
made from the polylactones: the evaporated 1% hydrocortisone composites and the 1% 
hydrocortisone composite caplets. Respect to the absolute values, in the second scan, 
the difference in the results for these series of materials is within 1ºC for the melting 
point, and within 3% in the enthalpy value, showing that crystallization is not 
significantly modified by the addition of the hydrocortisone neither by the method of 
preparation (precipitated powder or caplets). However, the difference in absolute values 
is bigger for the first scan, as a consequence of the previous thermal history of the 
material. For this reason, we have determined as precisely as possible (Table I) the 
crystallization value of the 1% hydrocortisone caplets, which are the samples tested for 
hydrocortisone release. 
The WAXS difractograms show a typical crystalline pattern of PCL crystals 
(peaks at 21.5 and 23.8, corresponding to PCL) [13]. The observed pattern for HA-PCB 
pattern is alike to those observed for HA-PCL and HBz-PCL, showing that the presence 
of BL does not have an important effect in the crystalline pattern observed by WAXS. 
Degradation rates are significantly different for copolymer with respect to 
homopolymers, but only a small difference could be detected between HA-PCL and 
HBz-PCL.  
3.2   Hydrolytic acid degradation of polymer caplets  
In order to test the degradation properties of caplets, an accelerated stability test 
was performed. Degradation test performed at pH = 7.4 phosphate buffer (physiological 
conditions) involves degradation times ranging from one to two years. Accelerated 
degradation methods allow obtaining degradation results in a shorter period of time. The 
in vitro hydrolytic degradation of polylactone caplets were carried out at 37°C in 0.5 M 
aqueous p-toluenesulfonic acid as degradation catalyst [4].  
 The possible factors contributing to accelerated degradation are the degree of 
crystallinity and the nature and number of the end groups [9, 15]. 
Figure 2 illustrates the weight loss occurred after immersion in 0.5 M aqueous p-
toluenesulfonic acid at 37 °C. As it can be seen, and taking into account the values of 
CL crystallinity and of the remaining amorphous material for these polylactones, at the 
experimental conditions tested the degradation depends also on 1) the chemical 
structure of the chain and 2) the nature of end groups. For the homopolymers, the lower 
crystallinity of the HBz-PCL polymer respect to HA-PCL polymer is compensated by 
the hydrophobicity of the benzyl group respect to the carboxylic group, and both 
homopolymers follow the same degradation profile. For the copolymer HA-PCB, with 
carboxylic acid end groups and molecular weight practically the same as for 
homopolymer HA-PCL, the effect of the introduction of the BL units, less stable to 
hydrolysis than CL units, combined with a higher amount of amorphous material, leads 
to a faster degradation rate.  
 Surface morphology changes were followed by SEM. Figures 3, 4 and 5 show 
the SEM micrographs of HA-PCL caplets before degradation and after 8 and 22 days 
respectively under hydrolytic acid degradation. These images are consistent with a 
degradation mechanism by erosion. Initially, the surface appears fairly flat, and surface 
morphology is induced by the mold used for compression molding. After 8 days of 
degradation by p-toluensulfonic acid, a homogeneous and porous structure indicating 
hydrolytic attack at the amorphous phase at the surface is observed. After 15 and 22 
days, the severity and frequency of surface cracks increased with the time. Similar 
behavior is observed for HBz-PCL (not shown) and HA-PCB polylactones, although for 
HA-PCB, the appearance of cracks began earlier, at 8 days of hydrolytic degradation 
(see Fig. 6). 
3.3 In vitro drug release studies of polylactones caplets 
 Polymer samples with no residual monomers (less than 0.1% as determined by 
1H-NMR) were used for the tests. The model low molecular weight drug was 
hydrocortisone, which is a hydrophobic molecule. A hydrophobic drug is supposedly 
more compatible with the polyester carrier, hydrophobic in nature, and the resulting 
composite should be stable with time, avoiding a possible leaching of the drug, that 
would be more likely if the drug were hydrophilic in nature. In addition, if drug was not 
soluble on the polymer, would form microdomains of pure drug embedded in the 
polymeric matrix, and the release profile would not be probably steady, but irregular. A 
1% weight concentration of hydrocortisone was chosen as this is the usual concentration 
found on commercial formulations. 
The release profiles for hydrocortisone at two different pH values for three 
formulations are shown in Fig. 7 and 8. The release of hydrocortisone was a two-stage 
process: an initial rapid release stage (burst; value calculated by visual observation from 
the change in the curve slope) followed by a second slower release stage. At 55 days, 
the amount of hydrocortisone released from HA-PCB caplets was about 75%, while 
HBz-PCL and HA-PCL tablets released about 31% and 26% of their initial 
hydrocortisone content, respectively. Only a limited influence of pH was observed, with 
a slightly faster release at acid pH, being the difference of 10% for the caplets prepared 
with HA-PCB, and 4% for HA-PCL. A higher burst was observed for HA-PCB (44 ± 
4%), and HA-PCL and HBz-PCL formulations showed a burst significantly lower than 
HA-PCB (12 ± 2% and 18 ± 1% respectively). Concerning the second stage of 
hydrocortisone release, the three polylactones displayed a controlled delivery of 
hydrocortisone for more than 40 days. 
When crystallization occurs, the crystallizing phase is a pure phase, and 
therefore, in the prepared samples, the drug is supposedly dissolved in the amorphous 
phase of the semicrystalline carrier, which in turn is the more accessible phase for 
degradation. For the homopolymers, with similar degradation rates, the hydrocortisone 
release at the burst is related to the amount of amorphous material, and release is faster 
for HBz-PCL. After the burst, the slope for the release trace is related to the degradation 
rate, and therefore is the same for both homopolymers. For copolymer HA-PCB, 
amorphous material measured by DSC starting from 25ºC is similar to HBz-PCL 
homopolymer (see column 9 of Table 1). However, melting endotherm is quite 
different, and the melting temperature is in the order HA-PCL > HBz-PCL > HA-PCB. 
At the test temperature, 37ºC, part of the crystallinity calculated by DSC is lost, and in 
more extent for the HA-PCB copolymer, resulting on a higher initial burst. In summary, 
the amount of amorphous phase exposed by the polymer at the test temperature seems 
to govern the initial burst during release. 
Once the initial burst is overcome, the release rate is more related to the 
degradation rate of the carrier. The slope of the linear steady release profile at the 
second stage is higher for the copolymer than for the homopolyesters, demonstrating 
again that degradation rate is higher due to the inclusion of labile BL units. For the two 
polycaprolactone homopolymers, having the same degradation rate as already shown in 
figure 1, the observed slope is almost the same.  
Kinetics and mechanism of drug release. 
 Results of the drug release study are reported in terms of diffusion efficiency, 
calculated considering the entire time interval 0-55 days, over which the release curves 
that are depicted in fig. 7 and 8 were registered. 
 Kinetics and release mechanisms can be evaluated on the basis of the equation of 
Ritger and Peppas [16-18]. 
 
Mt/M∞ = k tn 
 
Where Mt/M∞ is the fraction released at time t, k is a proportionality constant 
which takes into account the matrix characteristics, and n is an exponent whose value is 
indicative of the drug release mechanism. The equation was applied to the first 60% of 
fractional release from caplets like Ritger and Peppas suggested. The parameters k and n 
can be obtained from initial experimental data trough square root of dimensionless time 
and the fraction release values ≤ 0.60 to the resulting linear curves. This analysis gives k 
and n as slope and exponent, respectively. The values of k and n obtained from the 
curves of the different matrices are reported in table 2. 
 It can be seen that n values varied from 0.85 to 1.13. Taking into account the 
criteria assumed to be valid in the treatment of drug release from non-swellable 
devices[19], these values suggest that release mechanism could be considered, in a 
general way, as non-Fickian. However, obtained values were very close to the zero 
order limit of n = 1, where the corresponding release mechanism (rate of hydrolysis) is 
independent of time. 
 
CONCLUSIONS 
In this work, we investigated how the polymer architecture (different functional 
end groups or insertion of a second monomer) can affect the behaviour of polylactone 
caplets in the release of a hydrophobic drug. 
Degradation studies have shown that in these semicrystalline polylactones of 
similar molecular weight and with degree of crystallinity in the same order, the effect of 
the end-group for Mn values above 2000 Da is not very significant, and the inclusion of 
more labile co-monomers is determinant to increase the degradation rate. 
The release of a hydrophobic drug, hydrocortisone, at a 1% weight 
concentration, takes place in two differentiate stages: an initial burst mainly influenced 
by the amount of amorphous material on polymeric carrier at the 37ºC of the test 
temperature, stronger when crystallinity is lower, and a linear stage mainly influenced 
by the hydrolytic stability of the polymeric carrier, dependent on the inclusion of labile 
co-monomers. Release rate is increased at acid pH as expected, although this effect is 
not very strong, with a difference of 10% for the copolymer HA-PCB, and 4% for 
polycaprolactone HA-PCL. 
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TABLE 1.  Thermal characteristics and degradation properties of polylactone caplets 
containing 1% hydrocortisone. 
 
a Obtained by 1H-NMR  
b Obtained by GPC-MAALS; P.I. = Polydispersity index: Mw/Mn 
c Calculated from the CL content in the polylactone and ratioing against crystallization 
heat for pure high molecular weight PCL 16.9 KJ/mol [20]   
d Weight of (non- crystallized CL + end groups + 1% hydrocortisone) for 
homopolymers, and (+ BL content) for the copolymer  
 
 
 
 
 
TABLE 2. Values k and n (± 95% confidence intervals) obtained by plotting 
hydrocortisone fraction release vs square root of dimensionless time curves from slabs 
of different compositions at pH 5.0 and 7.4. R2 values are also reported.  
 
Matrix k n R2 
HA-PCL (pH 7.4) 0.17 ± 0.09 0.85± 0.03 0.991 
HA-PCL (pH 5.0) 0.15 ± 0.01 0.92± 0.02 0.994 
HBz-PCL (pH 7.4) 0.16 ± 0.01 1.05 ± 0.09 0.990 
HBz-PCL (pH 5.0) 0.16 ± 0.01 1.03 ± 0.04 0.997 
HA-PCB (pH 7.4) 0.15 ± 0.02 1.13 ± 0.13 0.984 
HA-PCB (pH 5.0) 0.15 ± 0.18 1.10 ± 0.11 0.988 
 
 
FIGURE CAPTIONS 
 
Fig.1. DSC thermograms of PCL copolymer and PCL homopolymers (HA-PCB, HBz-
PCL and HA-PCL).  
Fig.2. Hydrolytic degradation of polylactone tablets by immersion in 0.5 M aqueous p-
toluene sulfonic acid at 37°C (■) HA-PCL, (●) HBz-PCL and (▲) HA-PCB. Means and 
S.E.M. are shown. 
Polylactone Mna  Mnb  Mwb P.I.b Tm 
(°C) 
ΔHm 
(J/g) 
%CLc 
cryst. 
% weightd 
amorphous 
Degradation 
Rate (%/day) 
HA-PCL 2920 4000 6500 1.63 65.4 121.7 83.5 13.8 1.36 
HBz-PCL 2810 5500 6600 1.20 60.3 110.5 78.4 20.7 1.43 
HA-PCB 2130 3900 5400 1.38 57.5 110.9 80.7 20.7 1.72 
Fig.3. SEM micrograph of HA-PCL caplets before hydrolytic acid degradation. 
Fig.4. SEM micrograph of HA-PCL caplets after 8 days of hydrolytic acid degradation. 
Fig.5. SEM micrograph of HA-PCL caplets after 22 days of hydrolytic acid 
degradation. 
Fig.6. SEM micrograph of HA-PCB caplets after 8 days of hydrolytic acid degradation. 
Fig.7. Release profiles of hydrocortisone from caplets compressed at 4 ton evaluated in 
buffer at pH 7.4 and 37°C .  
Fig.8. Release profiles of hydrocortisone from caplets compressed at 4 ton evaluated in 
buffer at pH 5.0 and 37°C. 
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Fig.5. SEM micrograph of HA-PCL caplets after 22 days of hydrolytic acid 
degradation. 
 
 
 
 
 
 
 
 
 
 
 
Fig.6. SEM micrograph of HA-PCB caplets after 8 days of hydrolytic acid degradation. 
 
 
 
 
 
 
  
 
 
Fig.7. Release profiles of hydrocortisone from caplets compressed at 4 ton evaluated in 
buffer at pH 7.4 and 37°C .  
 
 
 
 
 
 
 
 
  
 
 
 
 
Fig.8. Release profiles of hydrocortisone from caplets compressed at 4 ton evaluated in 
buffer at pH 5.0 and 37°C. 
 
